Evidence map›Paper›PMID 27536188›Full record

ReviewCurrent oncology (Toronto, Ont.)2016

High-grade glioma management and response assessment-recent advances and current challenges.

M N Khan, A M Sharma, M Pitz, S K Loewen, H Quon, A Poulin, M Essig

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology (Toronto, Ont.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

M N KhanDepartment of Radiology, University of Manitoba, Winnipeg, MB;
A M SharmaDepartment of Radiology, University of Manitoba, Winnipeg, MB;; Department of Radiation Oncology, CancerCare Manitoba, Winnipeg, MB;
M PitzDepartment of Internal Medicine, University of Manitoba, Winnipeg, MB;; Department of Haematology and Medical Oncology, University of Manitoba, Winnipeg, MB;
S K LoewenDepartment of Radiology, University of Manitoba, Winnipeg, MB;; Department of Radiation Oncology, CancerCare Manitoba, Winnipeg, MB;
H QuonDepartment of Radiology, University of Manitoba, Winnipeg, MB;; Department of Radiation Oncology, CancerCare Manitoba, Winnipeg, MB;
A PoulinDepartment of Radiology, University of Manitoba, Winnipeg, MB;; Department of Radiology, Laval University, Quebec City, QC.
M EssigDepartment of Radiology, University of Manitoba, Winnipeg, MB;

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The management of high-grade gliomas (hggs) is complex and ever-evolving. The standard of care for the treatment of hggs consists of surgery, chemotherapy, and radiotherapy. However, treatment options are influenced by multiple factors such as patient age and performance status, extent of tumour resection, biomarker profile, and tumour histology and grade. Follow-up cranial magnetic resonance imaging (mri) to differentiate treatment response from treatment effect can be challenging and affects clinical decision-making. An assortment of advanced radiologic techniques-including perfusion imaging with dynamic susceptibility contrast mri, dynamic contrast-enhanced mri, diffusion-weighted imaging, proton spectroscopy, mri subtraction imaging, and amino acid radiotracer imaging-can now incorporate novel physiologic data, providing new methods to help characterize tumour progression, pseudoprogression, and pseudoresponse. In the present review, we provide an overview of current treatment options for hgg and summarize recent advances and challenges in imaging technology.

Indexed as

diffusionGliomasperfusionpseudoprogressionpseudoresponse

Identifiers

PMID27536188
PMCPMC4974045

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.